Search

Protein engineering has made it possible to combine the binding sites of murine antibodies with human antibody regions. Antibodies constructed in this way have important advantages for therapy.

The introduction of cloned genes into eukaryotic cells has become a major technique in the study of gene expression. Many experiments have demonstrated transcription of cloned genes after transfection into heterologous cell systems--cells in which the genes are not normally active. More recently, several investigators have obtained expression of specialized genes after transfection into cells of the corresponding specialized type, notably the beta-globin gene in erythroleukaemic cells and immunoglobulin genes in myeloma cells. These results allow the study of gene expression during development by comparing transcription of a gene transfected into homologous and heterologous cells. We have shown that a rearranged kappa immunoglobulin gene, cloned from a mouse myeloma, is transcribed transiently at a high level when reintroduced into mouse myeloma cells. We show here, in an internally controlled manner, that the same immunoglobulin gene is not detectably transcribed when transfected into mouse 3T3 or L cells.

Antibodies and growth factors have been chemically coupled to different toxins to produce cytotoxic molecules that selectively kill cells bearing appropriate antigens or receptors. Antibody-toxin conjugates (immunotoxins) produced using conventional chemical coupling techniques have several undesirable characteristics. The smallest binding unit of an antibody is an Fv fragment which consists of a light and heavy chain variable domain. Recently, active single chain Fv fragments of antibodies have been produced in Escherichia coli by attaching the light and heavy chain variable domains together with a peptide linker. Here we describe the construction and expression in E. coli of a single chain antibody toxin fusion protein, anti-Tac(Fv)-PE40, in which the variable regions of anti-Tac, a monoclonal antibody to the p55 subunit of the human interleukin-2 receptor, are joined in peptide linkage to PE40, a modified form of Pseudomonas exotoxin lacking its binding domain. Anti-Tac(Fv)-PE40 was very cytotoxic to two interleukin-2 receptor-bearing human cell lines but was not cytotoxic to receptor-negative cells.

Recent studies in which cloned immunoglobulin genes were introduced into cultured cells have produced two significant findings. First, the genes are expressed after transfection into lymphoid cells but not non-lymphoid cells. Second, transcription of an immunoglobulin gene requires, in addition to the promoter region, an enhancer element located downstream of the transcription start site. These findings raise the question of whether it is the promoter or the enhancer region that is responsible for the observed cell-type specificity. It has, in fact, been shown that immunoglobulin enhancers function only in lymphoid cells. We show here that the promoter for an immunoglobulin kappa light-chain gene also is strongly specific for lymphoid cells. Our result reemphasizes the importance of promoters relative to enhancers in determining which cells express which genes.

Enhancers are DNA sequences that stimulate transcription from eukaryotic promoters. This stimulatory effect can be exerted over large distances and from a position either 5' or 3' of a promoter. Enhancers have been found in the genomes of many viruses, and in some cellular genes such as those encoding immunoglobulin heavy chain and kappa light chain. An important feature of both viral and cellular enhancers is the ability of each enhancer to stimulate transcription from many promoters other than the one with which it is found associated. However, the question of whether cellular enhancers stimulate their 'own' promoter more efficiently than other promoters has apparently not been investigated. We show here that the kappa light-chain enhancer stimulates a kappa promoter about 20-fold more than it stimulates either the simian virus 40 (SV40) early promoter or a metallothionein (MT) promoter, two promoters that are very sensitive to other enhancers. Similarly, the heavy-chain enhancer stimulates a heavy-chain promoter much more than it stimulates the SV40 and MT promoters. This synergism between immunoglobulin enhancers and promoters might be due to the action of a protein that binds specifically to each of the regulatory elements.